20190604 - Chromsystems Industry Workshop - IWT113 - 0730-0830 |
Chromsystems Industry Workshop
Session Title:
Drugs Screening in Urine Using a Novel Fully Validated LCMS Assay
Presenters:
Huda Cathum, Chromsystems Instruments & Chemicals GmbH
Joseph Macri, Clinical Pathology, Hamilton General Hospital
Matthew Nichols, McMaster University, Molecular Genetics and Pediatric
Objectives:
At the conclusion of this session, participants will be able to:
1. Our goal is to explain how this Health Canada-approved new assay for the screening and simultaneous quantitation of 108 drugs/metabolites in urine can help clinical laboratories. Special focus will be placed on why and how a commercial assay can provide superior and reliable results with the ultimate goal of exceptional patient care. Data will be compared with immunoassay and GC-MS-based methods. The performance characteristics are described and the quality and regulatory background will be discussed.
Presenters:
Huda Cathum, Chromsystems Instruments & Chemicals GmbH
Joseph Macri, Clinical Pathology, Hamilton General Hospital
Matthew Nichols, McMaster University, Molecular Genetics and Pediatric
Objectives:
At the conclusion of this session, participants will be able to:
1. Our goal is to explain how this Health Canada-approved new assay for the screening and simultaneous quantitation of 108 drugs/metabolites in urine can help clinical laboratories. Special focus will be placed on why and how a commercial assay can provide superior and reliable results with the ultimate goal of exceptional patient care. Data will be compared with immunoassay and GC-MS-based methods. The performance characteristics are described and the quality and regulatory background will be discussed.